Fujirebio Europe
Technologiepark 6
9052 Zwijnaarde
BE
Fujirebio Europe
Foundation date
18/07/1985
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Endocrine - nutritional and metabolic diseases
- #Infectious and parasitic diseases
- #Mental and behavioural disorders
- #Neoplasms / cancer / oncology
Fujirebio is a global leader in the field of high quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states.
Upcoming events
All events-
0712 '22
Emerging Applications of Microbes (2nd edition)
Event by: VIB -
1212 '22
Type 2 Immunity in Homeostasis and Disease (2nd edition)
Event by: VIB -
2911 '22
BioFIT 2022
Event by: Eurasanté
Latest news
More news-
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
14 hours ago
Read more
-
Indigo Diabetes announces first participant enrolled in the SHINE clinical trial
Thursday September 29th 2022
Read more
-
FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome
Tuesday September 27th 2022
Read more